Short-term use of high-flow nasal tubes can help patients experiencing exacerbations of their chronic obstructive pulmonary disease, according to a study in Respirology.
Short-term use of high-flow nasal tubes can help patients experiencing exacerbations of their chronic obstructive pulmonary disease (COPD), according to a study in Respirology.
The researchers from the Medical Research Institute of New Zealand and the University of Otago Wellington studied the effects of nasal high-flow cannulae on increased arterial carbon dioxide tension, which is a complication of acute exacerbations of COPD.
The study included 24 hospital inpatients with acute exacerbations of COPD who were receiving oxygen via nasal prongs. The patients received both supplemental oxygen via nasal high-flow cannulae at 35 L/min and standard nasal prongs for 30 minutes each. There was a 15-minute washout between each intervention.
The researchers found that patients had lower levels of retained carbon dioxide after 30 minutes of nasal high-flow cannulae compared with the standard nasal prongs.
“These findings suggest that this novel way of delivering oxygen therapy to patients with an exacerbation of COPD may result in a small reduction in carbon dioxide levels,” said Richard Beasley, MBChB, FRACP, co-author of the study, said in a statement.
Although the study found that short-term use of nasal high-flow cannulae reduced transcutaneous carbon dioxide tension by a small amount, the researchers were unsure if it was a clinically significant outcome. Furthermore, there was no difference in oxygen saturation and the reduction in respiratory rate for nasal high-flow cannulae was not statistically significant.
“Further research to assess the clinical utility of nasal high-flow oxygen therapy in patients who experience exacerbations of COPD is now a priority,” Beasley said.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More